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Role of receptor-associated 39/45 kD protein in active Heymann
Nephritis. Active Heymann nephritis (HN) of rat, an autoimmune gb-
merular disease, is an experimental model of human membranous gb-
merulonephropathy (MGN), a common human glomerular disease. The
putative autoantigen of HN is believed to be a large glycoprotein (gp330)
present in kidneys of rat and human. Gp330 has sequence homology to low
density lipoprotein receptor-related protein (LRP)/a2-macroglobulin re-
ceptor and co-purifies with another 45 kD protein called receptor-
associated protein (RAP) which binds to both gp330 and LRP/a2-
macroglobulin receptor. Since RAP co-purifies with gp330 and is thus
present in the immunizing material used to induce active HN, the present
study was undertaken to determine if gp330 or RAP individually could
produce active HN and whether RAP had a role in the pathogenesis of
active HN. Rats immunized with the traditional crude antigen (Fx1A)
containing both gp330 and RAP developed typical HN. Although these
rats developed low titers of autoantibody to RAP in their sera, they had no
deposition of antibody to RAP in their kidneys. Rats immunized with
gp330 also developed typical HN but had no autoantibody to RAP in their
sera or kidneys. Rats immunized with RAP developed high titers of
autoantibody to RAP in their sera but had no antibody in their kidneys
and did not develop HN. Three rats were injected intravenously with
polyclonal antibody to RAP and assessed seven days later for the
development of passive HN. All three developed mild passive HN
characterized by granular staining of polyclonal antibody along the
capillary loops. Conclusions: (1) This is the first report to show that gp330
alone without the accompanying RAP can induce active HN; (2) RAP by
itself does not induce active HN; (3) Autoantibodies to RAP do not
appear to be involved in the pathogenesis of active HN induced with the
traditional crude antigen, Fx1A; and (4) We confirm that polyclonal
antibody to RAP can induce passive HN.
Active Heymann nephritis (HN) of rat is an autoimmune
glomerular disease which has striking immunohistobogical, ultra-
structural, and clinical similarities to the human idiopathic mem-
branous glomerulonephropathy (MGN) and is widely used as an
experimental model for MON [1, 21. It is commonly produced by
immunizing rats with an emulsion of complete Freund's adjuvant
(CFA) and a crude renal cortical fraction called Fx1A [3]. The
putative autoantigen of HN is a mannose or glucose containing
large glycoprotein [4, 5] present on proximal renal tubular epithe-
hal cell [6, 7] and visceral glomerular epithelial cell [8]. The
disease results from the binding of autoantibodies to the auto-
antigen expressed on glomerular epithelial cell, leading to the
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formation of typical granular immune deposits along the glomer-
ular capillasy wall that stain positively for rat immunoglobulin G
(IgG) and complement when studied by direct immunofluores-
cence. When a certain threshold level of autoantibody deposition
and complement activation is reached, plasma proteins begin to
leak from the gbomerulus and appear in urine (proteinuria) [9].
Using lectin affinity chromatography, the autoantigen of active
RN was independently purified from FX1A by us [10] and from
kidney brush border microvilli by Kerjaschki and Farquhar [11].
We estimated its molecular weight by gel filtration to be approx-
imately 600 kD and therefore designated it as gp600 [10, 12].
Kerjaschki and Farquhar [11, 13], using sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), estimated the
molecular weight to be approximately 330 kD and gp330 became
the more commonly used terminology. Although recent work
from several laboratories, [14—18] supports our estimate of its
molecular weight, to prevent confusion we have elected to retain
the term gp330 in this communication. gp330 has also been shown
to be present in human kidney [19]. Partial cDNAs of rat gp330
have been cloned [20] and show homology to low density lipopro-
tein [LDL] receptor [21] and LDL receptor related protein
(LRP)/a2-macroglobuhin receptor [22—24]. Recently, plasminogen
[251, plasminogen activator-inhibitor complex [16, 18], hipoprotein
lipase [16, 17], and lactoferrin [16] have been identified as ligands
for gp330. We first showed that another kidney protein of 45 kD
with eDNA distinct from the eDNA of gp330 could also bind to
gp330 when tested by Western analysis [26, 27]. Subsequently, this
protein, 39 kD in humans [28] and 45 kD in rat [27], has been
identified to be associated with gp330 and LRP and thus desig-
nated receptor associated protein (RAP) [15, 28]. RAP co-purifies
with gp330 during laboratory isolation of gp330 through lectin
affinity chromatography [15] and is thus present in gp330 prepa-
rations used to immunize rats to induce active HN. The purpose
of this study was to determine if RAP or gp330 alone could
produce active RN and to study the role of RAP in the patho-
genesis of active HN induced by active immunization with the
traditional crude antigen, FX1A.
Methods
Animals
Female Lewis rats, weighing 150 to 200 grams, were obtained
from Charles River Lab (Wilmington, MA, USA).
Reagents
Complete Freund's adjuvant (CFA) was obtained from Difco
Lab (Detroit, MI, USA). Fluorescein isothiocyanate (FITC)
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Fig. 1. SDS-PAGE analysis of punfied RAP. Proteins (2 rg in each lane)
were electrophoresed in 10% SDS-PAGE gel under non-reducing condi-
tions and stained with Coomassie blue. Lane 1, prestained low molecular
weight markers; lane 2, electroeluted RAP from a preparative PAGE gel;
lane 3, GST; and lane 4, GST-RAP fusion protein.
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Fig. 2. Autoantibody to RAP in serum measured by ELISA. Serum samples
from week zero (pre-immunization) to week 16 (sacrifice time) from 10
rats immunized with rat Fx1A (•) and 10 rats immunized with GST-RAP
fusion protein (0) were tested by ELISA on microtiter plates coated with
electroeluted purified RAP. Autoantibody measured as absorbance at
490 nm is shown along the y axis and time (weeks) following the first
immunization along the x axis. Serum samples from rats immunized with
GST-RAP fusion protein were diluted 1:8000 and those from immunized
with rat Fx1A diluted 1:50. Thus, the curve depicting autoantibody level in
RAP immunized rats was generated from sera that were 160-fold dilute
than the sera used to generate the curve for FX1A immunized rats.
Peroxidase-labeled goat anti-rat IgG was diluted 1:10000. Absorbance
values at each time point represent mean SEM of duplicates of 10
samples each.
conjugated rabbit anti-rat IgG and third component of comple-
ment (C3) and goat antirabbit IgG were obtained from Cappel
Lab (Malvern, PA, USA). Polyclonal antibody to rat membrane
attack component of complement (C5b-9) was prepared in rabbit
as described previously [91. All reagents for SDS-PAGE and
Western analysis were obtained from Biorad Lab (Richmond, CA,
Fig. 3. Western blot analysis of autoantibody to RAP in sera and glomerular
eluates from rats immunized with rat FxIA, GST-RAP fusion protein, or
gp330. RAP (2 ig in each lane) was electrophoresed in 10% SDS-PAGE
gel under non-reducing conditions and transferred to a nitrocellulose
membrane. Lane 1 was reacted with normal rat serum (1:20 dilution), lane
2 reacted with serum from a rat immunized with rat Fx1A (1:20), lane 3
with glomerular eluate from a rat immunized with rat Fx1A (1:5), lane 4
with serum from a rat immunized with rat gp330 (1:20), and lane 5 reacted
with serum from a rat immunized with GST-RAP fusion protein (1:400).
All lanes were reacted with peroxidase-labeled goat anti-rat IgG (1:400).
USA). Nitrocellulose membrane was obtained from Schleicher &
Schnell (Keene, NH, USA). Polystyrene, microtiter plates for
enzyme-linked immunosorbent assay (ELISA) were obtained
from Corning (Corning NY, USA). Rat kidneys were obtained
from Pel Freeze (Rogers, AR, USA). Glutathione-conjugated
agarose was obtained from Sigma Chemical Co. (St. Louis, MO,
USA). Thrombin was obtained from Boehringer Mannheim (In-
dianapolis, IN, USA). D-phenylalanyl-prolyl-l-arginine chioro-
methyl ketone (PPACK) was obtained from Calbiochem (La
Jolla, CA, USA).
Antigens
Rat crude kidney antigen (Fx1A) was prepared from rat kidneys
as described before by Edgington et al [31. Rat gp330 was
prepared from sodium desoxycholate solubilized rat Fx1A by gel
filtration, lectin affinity chromotography and electroelution of the
gp330 band from a preparative SDS-PAGE gel as described
previously [29]. The electroeluted gp330 band was again tested for
purity and contained no RAP as assessed by SDS-PAGE and
Western blot analysis using rabbit polyclonal antibody to rat RAP.
Rat recombinant RAP was prepared as follows.
Purification of glutathione S-transferase, GST-RAP fusion pro-
tein. The salmonella japonicum glutathione S-transferase (GST)-
RAP expression plasmid containing full length cDNA of rat RAP
was a gift of Dr. Joachim Herz [30]. GST-RAP fusion protein was
overexpressed in DH5a bacteria and purified by affinity chro-
matograpgy on a glutathione-agarose column as described by
Herz et al [30]. The purity of GST-39 kD fusion protein was
assessed by SDS-PAGE. This GST-RAP fusion protein was used
as an immunogen to immunize rats to induce AHN.
Purification of RAP. Since rats were immunized in the GST-
RAP fusion protein, they could make antibodies to both GST and
RAP. In order to differentiate these antibodies by ELISA and
/
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Fig. 4. Autoantibody to RAP in serum detected by indirect immunofluorescence. Serum from a rat immunized with GST-RAP fusion protein was studied
by indirect immunofluorescence on a snap-frozen unfixed normal rat kidney section (4 m) using FITC labeled rabbit anti-rat IgG. Fluorescence in the
brush border microvillar region of proximal renal tubules is seen (magnification 400X).
Western blot analysis, a preparation of RAP without the accom-
panying GST was needed. To prepare RAP without GST, the
GST-RAP fusion protein was subjected to two additional purifi-
cation steps. First, the RAP was cleaved off from the GST-RAP
fusion protein by thrombin treatment. Fractions of GST-RAP
fusion protein were pooled and dialyzed against 20 mrvi Hepes, 50
mM NaC1, 2.5 mvt CaC12 pH 7.4, and incubated with 3 U of
thrombin/5 mg of fusion protein at 37°C. After four hours,
another three U of thrombin/5 mg protein were added and
incubation continued overnight. Reaction was stopped by adding
PPACK at a ratio of io mole of PPACK to 10—8 mole of
thrombin. The digested protein solution was reapplied to freshly
equilibrated glutathione-agarose column and the unabsorbed
material containing the cleaved purified recombinant RAP saved
and analyzed for purity by SDS-PAGE. Second, the above RAP
was further purified by preparative PAGE on a 3 mm thick 10%
SDS-PAGE gel under non-reducing conditions by using the
discontinuous buffer system of Laemmli [311. The location of RAP
was determined by staining the outer lane with 0.2% Coomassie
brilliant blue in 40% methanol, 10% acetic acid for 30 minutes
and destained in 40% methanol and 10% acetic acid for one hour.
The rest of the gel was kept at 4°C. The gel strip corresponding to
RAP band was cut out of the unstained gel and electroeluted
using an electroelution cell (Elutrap, Schleicher and Schuell, Inc.)
in 0.025 M Tris-0.192 M glycine, pH 8.3, 0.1% SDS buffer at 100 V
for 20 hours at room temperature. The electroeluted RAP was
assessed further for purity and homogeneity by SDS-PAGE.
Induction of active HN
Active HN was induced in female Lewis rats in a standard
manner by immunizing with the test antigen emulsified in CFA, as
described previously [12]. Group 1 (N = 10) was immunized with
rat Fx1A, group 2 (N = 10) with recombinant rat GST-RAP
fusion protein, and group 3 (N = 3) with purified electroeluted rat
gp330 band. The first immunization was given intracutaneously,
divided among one hind foot pad and multiple sites on back.
Booster immunizations were given subcutaneously at four and
eight weeks, respectively, after the first immunization. For the first
immunization each rat in group 1 received 10 mg of Fx1A, in
group 2, 500 g of GST-RAP fusion protein, and in group 3, 100
ig of rat gp330, respectively. The dose for the booster immuni-
zations was one-half of the dose of the first immunization for each
antigen. Sera were collected prior to immunization and every 4
weeks subsequently. Twenty-four urines were collected prior to
immunization and every two weeks, starting at six weeks of the
first immunization. Total protein in urines was determined by
sulfosalicylic acid method as described previously [12]. Rats were
sacrificed at 16 weeks, and their kidneys analyzed for the devel-
opment of active HN by performing direct immunofluorescence
on snap-frozen unfixed kidney sections for the presence of typical
Fig. 5. Absence of the active HN lesions in rats immunized with GST-RAP fusion protein. Four tm unfixed frozen kidney sections were reacted with
FITC-labeled rabbit anti-rat IgU and studied by direct immunofluorescence (A). Rat immunized with GST-RAP fusion protein, (B) normal
unimmunized control rat, (C) rat immunized with Fx1A, (D) rat immunized with gp330. Typical lesion of active HN consisting of granular staining for
rat IgG is seen in rats immunized with Fx1A (C) and gp330 (D). Only background fluorescence for endogenous rat IgG is seen in rats immunized with
GST-RAP fustion protein (A) which is similar to the background fluorescence seen in a normal unimmunized control rat (B) (magnification 400X).
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Fig. 5. Continued.
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staining for rat IgG and C3 complement in glomeruli. The
technique for processing of tissue and immunofluorescence has
been previously described [32]. One kidney from each rat was
used to isolate glomeruli and elute IgG from glomeruli using an
acid buffer. The techniques for isolation of glomeruli and elution
of IgG from glomeruli have been described previously [29].
Enzyme-linked immunosorbent assay (ELISA)
Antibodies to RAP were determined by ELISA using the
standard ELISA procedure previously described in detail [33].
Briefly, microtiter plate wells were coated with purified thrombin
cleaved RAP or electroeluted RAP (5 j.g/ml) and reacted sequen-
tially with test sera, peroxidase labeled goat anti-rat IgG and
substrate solution (2.5 mM 0-phenylenediamine, 0.006% H202,
0.1 M phosphate/citrate buffer, pH 5.0) and the absorbance read at
490 nm before and after the addition of 50 d of 4N H2S04.
Appropriate controls of reaction of preimmune normal rat serum
and peroxidase-labeled goat anti-rat IgG alone on RAP coated
wells, and reaction of immune rat serum, normal rat serum and
peroxidase-labeled goat anti-rat IgG on non-RAP coated wells
(BSA) were included. All samples were analyzed in duplicates.
The mean absorbance of duplicates was calculated and the
background absorbance obtained with control samples subtracted
from the above mean. Titers of antibody in sera were determined
from serial dilutions of sera. The dilution immediately preceding
the highest dilution at which no autoantibody was detectable (that
is, absorbance value was similar to background) was considered as
the titer.
SDS-PAGE and Western analysis
Proteins were electrophoresed in 10% or 4 to 15% gradient
polyacrylamide gels under non-reducing conditions by using the
discontinuous buffer system of Laemmli [31] and transferred to
nitrocellulose as described before [33]. Nitrocellulose membrane
was blocked and reacted sequentially with test sera, peroxidase-
labeled goat anti-rat IgG, and substrate solution (0.05% 4-chloro-
1-napthol, 15% methanol, 0.015% H2O2 in PBS) as described
previously [33]. Appropriate controls of reaction with normal rat
serum and peroxidase-labeled second antibody alone were in-
cluded.
Induction of passive HN
A polyclonal antibody to rat RAP was prepared in rabbit by
immunizing with purified RAP. The antibody was characterized
for specificity by indirect immunofluorescence, ELISA and West-
ern blot analysis and found to be specific. Three normal rats were
injected intravenously with 1 ml of the antiserum each. The rats
were sacrificed a week later and their kidneys examined by direct
immunofluorescence for localization of rabbit IgG and rat IgG,
C3 and C5b-9. Twenty-four urines were collected prior to injec-
tion with antibody and prior to sacrifice and tested for total
protein.
Results
Purification of rat RAP
Successive purification of recombinant rat RAP from cell lysate
containing GST-RAP fusion protein through glutathione-agarose
affinity chromatography, thrombin cleavage of GST-RAP fusion
protein followed by passage through glutathione-agarose column,
and isolation of the RAP band by electroelution from preparative
PAGE gel resulted in a highly purified preparation of RAP.
Minor impurities were present in the preparation obtained from
glutathione-agarose affinity column following application of the
cell lysate. However, these impurities were eliminated during
further purification following thrombin cleavage and preparative
PAGE, and the final product was pure and homogeneous, as
assessed by SDS-PAGE (Fig. 1). The identity of the isolated RAP
was further confirmed by Western analysis using a polyclonal
antibody to native rat RAP produced as described earlier [27]. A
single band of reactivity was seen with this antibody by Western
analysis. Purified RAP was also tested for binding to gp330 by
ELISA and was found to bind to gp330.
Role of RAP in active HN
Immunization of rats with GST-RAP fusion protein RAP. All ten
rats immunized with recombinant RAP fusion protein developed
autoantibodies to RAP. The autoantibodies were detectable in
serum at the time of the first bleed (4 weeks) and throughout the
course until the rats were sacrificed at 16 weeks. The autoanti-
bodies were detectable by ELISA, Western blot analysis, and
indirect immunofluorescence on frozen, unfixed normal rat kid-
ney sections. At time of sacrifice, the titer of autoantibodies in
individual rats ranged from 1:10 to 1:100 by indirect immunoflu-
orescence and 1:64,000 to 1:256,000 by ELISA. No differences in
titers of autoantibody in RAP were seen by ELISA on plates
coated with RAP prepared by thrombin cleavage alone or elec-
troelution following thrombin cleavage. Antibody level as mea-
sured by absorbance at 490 nm by ELISA gradually increased
from week 4 to week 12 (Fig. 2). The results of autoantibody
detection from a rat at time of sacrifice by Western blot analysis
are shown in lane 5 in Figure 3 and by indirect immunofluores-
cence in Figure 4. By indirect immunofluorescence the autoanti-
body reacted with RAP present in the brush border region of the
proximal renal tubules on unfixed sections and with RAP in the
cytoplasm on periodote/lysine/paraformadehyde (PLP) fixed sec-
tions. No specific reaction was seen in glomeruli. Analyses of
kidneys at time of sacrifice by direct immunofluorescence showed
no granular staining typical for HN in glomeruli for rat IgG, or C3
and C5b-9 membrane attack components of complement in any
rat. Minimal staining for rat IgG in glomeruli was present (Fig.
5a), but it was no different in quantity or pattern of staining than
the control staining for endogenous rat IgG usually present in
normal rat kidney sections (Fig. Sb). No autoantibody to RAP
could be detected by any of the three methods in the glomerular
eluates in any rat. Protein excretion in 24 hour urine samples in all
these rats remained low (0.64 0.18 mg, mean SEM) and was in
the normal range throughout the course (Fig. 6). The normal
range of protein excretion in eight age and sex matched control
rats immunized with CFA only was 1.0 0.35 mg (mean sEM).
Immunization of rats with rat FxJA. All ten rats immunized with
rat Fx1A developed HN with typical immunohistology of MGN
consisting of granular staining for rat IgG (Fig. Sc), C3 and C5b-9
along capillary loops, and abnormal 24 hour proteinuria (Fig. 6).
The mean SEM protein excretion in 24 hour urine collections at
14 weeks after the first immunization was 58.18 12.71. All these
rats also developed autoantibodies to RAP as detected by ELISA;
however, the titers were only 1:50 to 1:100 (Fig. 2). Since both
anti-gp330 and anti-RAP autoantibodies react with the same
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Fig. 6. Proteinuria in rats immunized with GST-RAP fustion protein or
FxJA. Twenty-four hour urine protein excretion in 10 rats immunized with
RAP (0) or Fx1A (•) from week 0 to 16. Values at each time point
represent mean SEM of urines from 10 rats each. 24 hour urine protein
excretion in eight age and sex matched control rats immunized with
complete Freund's adjuvant alone was 1.0 0.35 mg.
anatomic site on proximal renal tubule, they could not be differ-
entiated by indirect immunofluorescence on frozen unfixed rat
kidney sections. However, they may be differentiated on PLP fixed
sections [27, 28]. On PLP fixed sections serum from these rats
reacted with only the brush border of proximal renal tubules and
no intracytoplasmic reaction was seen. This suggests that the titer
of autoantibody to RAP was very low. This is consistent with the
low titers detected by ELISA, which is a more sensitive assay than
indirect immunofluorescence. Faint reaction suggestive of low
level of autoantibody to rat RAP could be detected by Western
blot analysis; however, we could not photograph this faint reac-
tion. No autoantibody to RAP was detectable by any of the three
methods in the IgG eluted from glomeruli of rats immunized with
Fx1A.
Immunization of rats with rat gp330. All three rats immunized
with rat gp330 also developed typical immunohistology of MGN
(Fig. 5c) like the rats immunized with rat Fx1A, but had less
quantitative proteinuria (2.4 to 46.9 mg/24 hr). None of the rats
injected with rat gp330 developed autoantibodies to RAP, as
assessed by ELISA, Western blot analysis (Fig. 3) or indirect
immunofluorescence on PLP fixed sections (cytoplasmic fluores-
cence). No autoantibody to RAP was detectable in IgG eluted
from glomeruli of these rats.
Immunofluorescence studies on liver of GST-RAP fusion protein
immunized rats
Since RAP is present in hepatic cells, we analyzed frozen liver
sections for in-vivo localization of rat IgG by direct immunofluo-
rescence. No specific immunofluorescence for rat IgG was present
in livers of any of the animals, suggesting that in vivo no binding
of anti-RAP autoantibodies occurred in hepatocytes.
Passive HN induced by anti-RAP serum
In all three rats, small granular deposits staining for rabbit IgG
and rat C5b-9 were seen along the periphery of glomerular
capillary loops (Fig. 7). No staining was present for rat IgG. The
protein excretion in urine was in the normal range.
Discussion
This is the first report to show that immunization with gp330
alone can induce active HN in rat. In all previous reports [8,
10—12, 29, 34, 35] the gp330 or like preparations used to induce
active HN were most likely contaminated with RAP. This asser-
tion is based on the recent knowledge that RAP is noncovalently
bound to gp330 with high affinity (Kd = 8 nM) and invariably
co-purifies with gp330 [15]. Since none of the previously used
preparations of gp330 was tested for RAP, and in no case was an
isolated 330 kD band used for immunization, it is likely that they
all contained RAP. We subjected the traditional gp330 prepara-
tion to preparative PAGE and immunized animals with only the
gp330 band which did not contain RAP. Thus, gp330 alone
without the accompanying RAP can induce active HN.
The results of this study also provide evidence that RAP by
itself is not involved in the induction of active HN and that
autoantibodies to it do not accumulate in glomeruli of rats with
active HN. The evidence for this assertion is three-fold. First,
effective immunization with GST-RAP fusion protein does not
lead to the glomerular lesion of MGN. Second, in rats with active
HN induced by Fx1A that contains native RAP, no antibody to
RAP can be eluted from the glomerular lesion of MGN. Third,
immunization with gp330 alone can produce active HN and no
autoantibodies to RAP develop in these animals.
Immunization with RAP was performed with a fusion protein
consisting of GST and recombinant RAP obtained from a full
length cDNA of RAP. Therefore, it is likely that it contained the
immunogenic epitopes present on native RAP. Clearly, the im-
munizations were effective, since all ten immunized rats produced
large amounts of autoantibodies to RAP. However, none of the
rats had glomerular accumulation of anti-RAP autoantibodies in
their kidneys or developed abnormal proteinuria. Why the anti-
RAP autoantibodies in vivo do not localize in the glomerulus is
not clear. One possibility is that in vivo RAP is not expressed on
cell surface in the glomerular capillary wall in sufficient amounts
to form antigen-antibody complexes. This notion is consistent with
the recent results of Abbate et al [36]. These investigators
performed studies to explain the observations made earlier by
Orlando et al [37]. The latter investigators had observed that
anti-RAP antibodies, when studied immunohistologically, reacted
within the cytoplasm with the rough endocytoplasmic reticulum
(RER) in tissue sections fixed in periodate/lysine/paraformalde-
hyde (PLP), and with the brush border of microvilli in snap frozen
unfixed or acetone fixed tissue sections. Abbate et al confirmed
the findings of Orlando et al, but showed that the brush border
reaction of anti-RAP antibodies detected in unfixed snap-frozen
sections is due to an artifactual redistribution of endogenous RAP
that occurs during tissue processing. Their results showed that
during incubation of snap-frozen tissue section, endogenous RAP
was released in soluble form from its intracellular location in RER
and bound by gp330 present on the brush border of proximal
tubules. They also showed that endogenously RAP is present in
the cytoplasm but very little, if any, on cell surface of tubular or
glomerular cells. Prior to these studies, Kounnas et al had also
made a similar observation [15]. It is noteworthy that while gp330
could be readily demonstrated on the surface of the glomerular
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Fig. 7. Mild passive HN induced with polyclonal antibody to RAP. Four jrm unfixed, frozen kidney sections from a rat injected with 1 ml of antirat RAP
antiserum was reacted with FITC labeled goat anti-rabbit IgG and studied by direct immunofluorescence. Small fine granular deposits staining for rabbit
IgG can be seen along the periphery of glomerular capillary loops. Occasional fine granular deposits are also present in the cytoplasm of tubular cells
(magnification 400X).
podocytes, no RAP was detected on glomerular podocytes immu-
nohistochemically by electron microscopy, by neither Orlando et
al [37] nor Abbate et al [36]. These studies suggest that in vivo
most of the RAP is present in the cytoplasm of the glomerular
epithelial cell and probably not available for interaction with the
circulating anti-RAP autoantibody bathing the surface of the
glomerular epithelial cell in the glomerular capillary wall. An-
other possibility is that a small amount of RAP that is present on
surface does not contain the epiotopes to which the autoantibod-
ies are formed, since the autoantibodies are most likely elicited
against only a limited number of epitopes. It is also possible, as
suggested by Kounnas et al [15], that when RAP is bound to cell
surface receptors, such as the a2MR/LRP or gp330, the patho-
genic epitopes are hidden or masked. This may explain why no
glomerular accumulation of RAP autoantibody and a lesion like
Heymann nephritis was seen in animals immunized with OST-
RAP fusion protein. A similar explanation may also be responsi-
ble for the lack of localization of anti-RAP autoantibodics in vivo
in the liver.
Our results differ from those reported by Pietromonaco et al
[38]. These investigators immunized rats with a non-glycosylated
fusion protein produced in bacteria that were obtained from a
eDNA which they believed encoded for gp330. However, subse-
quent work has shown that their eDNA actually encoded for RAP
[15, 22—24]. They reported that these rats developed small subcp-
ithelial immune deposits containing endogenous rat IgG in gb-
merular capillary wall when sacrificed at 12 weeks. It was not
stated as to how many rats were immunized and how many
developed immune deposits, and whether the immunized rats
developed autoantibodies to the fusion protein in their sera or
had abnormal proteinuria. It was also not stated whether the small
deposits of rat IgG noted in immunized rat(s) were quantitatively
or in their site of location different from the endogenous rat IgO
normally detectable in the gbomerulus [39, 40] and whether the
deposits stained positively for complement. Also, no studies such
as elution of IgG from glomeruli of immunized rats, or other
studies to determine if the small amount of the IgG detected in
glomeruli was indeed autoantibody to RAP, were performed. In
the absence of the above information, it is difficult to know
whether the disease of active HN was induced in their study.
Our results of induction of a mild passive HN with polyclonal
antibody to RAP agree with the results of Pietromonaco et al [38].
However, Pietromanaco et al did not report if rat complement was
detectable in the passive HN lesion. We were able to detect
complement along with the injected antibody in passive HN;
however, no abnormal proteinuria was observed. How do these
positive results in passive HN reconcile with the negative results in
active HN? We believe this is probably explained by the variation
in epitope specificities of the autoantibodies induced by active
immunization of rat and those of the polyclonal antibodies
induced in rabbit as proposed in another model [41]. Since RAP
is a self antigen it is likely that the autoantibodies elicited by rat
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are to a limited number of epitopes. On the other hand, the
polyclonal antibodies are likely to be to many more epitopes. It is
possible that polyclonal antibody can find a few reactive epitopes
on the small amount of RAP present om glomerular epithelial
cells while those epitopes do not react with autoantibodies.
Further studies will be needed to resolve this issue. This also
raises another general question as to whether the antibodies
involved in the active HN induced by immunization with rat FX1A
and those involved in the passive model induced by intravenous
injection of antiserum to FX1A are to the same antigens and the
same epitopes on those antigens.
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